Race-specific drugs: regulatory trends and public policy

Trends in Pharmacological Sciences

Volumn 29, Issue 6, 2008, Pages 277-279

  Winickoff, David E ^a   Obasogie, Osagie K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Genetics and Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDRALAZINE PLUS ISOSORBIDE DINITRATE; N [3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL] 3 [2 (3 TERT BUTYLUREIDO) 3,3 DIMETHYL 1 OXOBUTYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE;

CLINICAL TRIAL; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SPECIFICITY; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; HEALTH CARE POLICY; HEART FAILURE; HEPATITIS C; HUMAN; LETTER; PRIORITY JOURNAL; RACE DIFFERENCE;

CONTINENTAL POPULATION GROUPS; DELIVERY OF HEALTH CARE; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 44549087763     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.03.008     Document Type: Letter

References (16)

1. Braun L., et al. Racial categories in medical practice: how useful are they?. PLoS Med. 4 (2007) e271. http://medicine.plosjournals.org 10.1371/journal.pmed.0040271
2. Lee S.S. Racializing drug design: implications of pharmacogenomics for health disparities. Am. J. Public Health 95 (2005) 2133-2138
3. Kahn J. How a drug becomes ethnic: law, commerce, and the production of racial categories in medicine. Yale J. Health Policy Law Ethics 4 (2004) 1-46
4. Puckrein G. BiDil: from another vantage point. Health Aff. (2006). http://healthaffairs.org 10.1377/hlthaff.25.w368
5. Temple R., and Stockbridge N.L. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective. Ann. Intern. Med. 146 (2007) 57-61
6. Tate S.K., and Goldstein D.B. Will tomorrow's medicines work for everyone?. Nat. Genet. 36 (2004) S34-S42
7. Taylor A.L., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Eng. J. Med. 351 (2004) 2049-2057
8. Epstein S. Inclusion: The Politics of Difference in Medical Research (2007), Chicago University Press pp. 223-225
9. Duster T. Race and reification in science. Science 307 (2006) 1050-1051
10. Lillquist E., and Sullivan C.A. The law and genetics of racial profiling in medicine. Harv. Civ. Rights-Civil Lib. Law Rev. 39 (2004) 391-483
11. Richmond v.J.A. Croson, 488 U.S. 469-563 (United States Supreme Court 1989)
12. Bloche M.G. Race, money, and medicines. J. Law Med. Ethics 34 (2006) 555-558
13. Kahn J. Genes, race, and population: avoiding a collision of categories. Am. J. Public Health 96 (2006) 6-11
14. Bibbins-Domingo K., and Fernandez A. BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval. Ann. Intern. Med. 146 (2007) 52-57
15. Washington H. Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present (2006), Doubleday
16. Gunther G. In search of evolving doctrine on a changing court: a model for a newer equal protection. Harv. Law Rev. 86 (1972) 1-48